Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.

IRIGItox causes major morbidity and mortality. Management is heterogeneous. CNIs appear most likely to result in toxicity resolution in the shortest time period, however, are associated with poorer oncological outcomes in contrast to vedolizumab.